BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Biotech catalysts in 2023-09
185 industry Phase 2/3 trial readout(s) and 35 FDA decision event(s). Readouts include completed (ACTUAL) and still-estimated primary completion dates in this month, any status.
FDA decision events
| Date | Event | Status | Company | Drug | Source |
|---|---|---|---|---|---|
| 2023-09-06 | FDA approval | approved | PFIZER PFE | IBRANCE | Approved 2023-09-06: IBRANCE (NDA207103 SUPPL17) |
| 2023-09-06 | FDA approval | approved | PFIZER PFE | IBRANCE | Approved 2023-09-06: IBRANCE (NDA212436 SUPPL5) |
| 2023-09-06 | FDA approval | approved | EMD SERONO INC | BAVENCIO | Approved 2023-09-06: BAVENCIO (BLA761049 SUPPL15) |
| 2023-09-07 | FDA approval | approved | PF PRISM CV | XALKORI | Approved 2023-09-07: XALKORI (NDA217581 ORIG1) |
| 2023-09-07 | FDA approval | approved | PF PRISM CV | XALKORI | Approved 2023-09-07: XALKORI (NDA202570 SUPPL36) |
| 2023-09-08 | FDA approval | approved | AYRMID PHARMA | APHEXDA | Approved 2023-09-08: APHEXDA (NDA217159 ORIG1) |
| 2023-09-12 | FDA approval | approved | SANDOZ | CYCLOPHOSPHAMIDE | Approved 2023-09-12: CYCLOPHOSPHAMIDE (NDA217150 ORIG1) |
| 2023-09-14 | FDA approval | approved | MERCK SHARP DOHME MRK | TEMODAR | Approved 2023-09-14: TEMODAR (NDA022277 SUPPL18) |
| 2023-09-14 | FDA approval | approved | MERCK SHARP DOHME MRK | TEMODAR | Approved 2023-09-14: TEMODAR (NDA022277 SUPPL19) |
| 2023-09-14 | FDA approval | approved | MERCK SHARP DOHME MRK | TEMODAR | Approved 2023-09-14: TEMODAR (NDA022277 SUPPL17) |
| 2023-09-14 | FDA approval | approved | MERCK SHARP DOHME MRK | TEMODAR | Approved 2023-09-14: TEMODAR (NDA021029 SUPPL37) |
| 2023-09-14 | FDA approval | approved | MERCK SHARP DOHME MRK | TEMODAR | Approved 2023-09-14: TEMODAR (NDA021029 SUPPL38) |
| 2023-09-14 | FDA approval | approved | MERCK SHARP DOHME MRK | TEMODAR | Approved 2023-09-14: TEMODAR (NDA021029 SUPPL36) |
| 2023-09-15 | FDA approval | approved | ACADIA PHARMS INC ACAD | NUPLAZID | Approved 2023-09-15: NUPLAZID (NDA207318 SUPPL12) |
| 2023-09-15 | FDA approval | approved | GENZYME CORP | NEXVIAZYME | Approved 2023-09-15: NEXVIAZYME (BLA761194 SUPPL5) |
| 2023-09-15 | FDA approval | approved | GLAXOSMITHKLINE | OJJAARA | Approved 2023-09-15: OJJAARA (NDA216873 ORIG1) |
| 2023-09-15 | FDA approval | approved | ACADIA PHARMS INC ACAD | NUPLAZID | Approved 2023-09-15: NUPLAZID (NDA210793 SUPPL9) |
| 2023-09-19 | Complete response letter | approved since | ARS Pharmaceuticals, Inc. SPRY | Neffy (ARS-1, epinephrine nasal spray), 2 mg/0 | CRL 2023-09-19: ARS Pharmaceuticals, Inc. NDA 214697 (Neffy (ARS-1, epinephrine nasal spray), 2 mg/0) |
| 2023-09-21 | FDA approval | approved | BOEHRINGER INGELHEIM | JARDIANCE | Approved 2023-09-21: JARDIANCE (NDA204629 SUPPL40) |
| 2023-09-22 | Complete response letter | approved since | Botanix SB Inc. | sofpironium bromide | CRL 2023-09-22: Botanix SB Inc. NDA 217347 (sofpironium bromide) |
| 2023-09-22 | FDA approval | approved | FABRE KRAMER | EXXUA | Approved 2023-09-22: EXXUA (NDA021164 ORIG1) |
| 2023-09-22 | FDA approval | approved | SAPTALIS PHARMS | LIKMEZ | Approved 2023-09-22: LIKMEZ (NDA216755 ORIG1) |
| 2023-09-25 | FDA approval | approved | FAMYGEN LIFE SCI | RYZUMVI | Approved 2023-09-25: RYZUMVI (NDA217064 ORIG1) |
| 2023-09-26 | FDA approval | approved | PF PRISM CV | BOSULIF | Approved 2023-09-26: BOSULIF (NDA203341 SUPPL25) |
| 2023-09-26 | FDA approval | approved | PF PRISM CV | BOSULIF | Approved 2023-09-26: BOSULIF (NDA217729 ORIG1) |
| 2023-09-27 | FDA approval | approved | TAKEDA PHARMS USA TAK | ENTYVIO | Approved 2023-09-27: ENTYVIO (BLA761133 ORIG1) |
| 2023-09-28 | Complete response letter | approved since | Eli Lilly and Company LLY | lebrikizumab injection | CRL 2023-09-28: Eli Lilly and Company BLA 761306 (lebrikizumab injection) |
| 2023-09-28 | FDA approval | approved | AMICUS THERAP US | POMBILITI | Approved 2023-09-28: POMBILITI (BLA761204 ORIG1) |
| 2023-09-28 | FDA approval | approved | AMICUS THERAP US | OPFOLDA | Approved 2023-09-28: OPFOLDA (NDA215211 ORIG1) |
| 2023-09-29 | Complete response letter | complete response | Galderma R&D, LLC | CRL 2023-09-29: Galderma R&D, LLC BLA 761311 | |
| 2023-09-29 | FDA approval | approved | NOVO NVO | RIVFLOZA | Approved 2023-09-29: RIVFLOZA (NDA215842 ORIG1) |
| 2023-09-29 | FDA approval | approved | BAXTER HLTHCARE CORP BAX | VASOPRESSIN IN SODIUM CHLORIDE 0.9% | Approved 2023-09-29: VASOPRESSIN IN SODIUM CHLORIDE 0.9% (NDA217569 ORIG1) |
| 2023-09-29 | FDA approval | approved | BIOGEN MA BIIB | TOFIDENCE | Approved 2023-09-29: TOFIDENCE (BLA761354 ORIG1) |
| 2023-09-29 | FDA approval | approved | CYCLOMEDICA | TECHNEGAS KIT | Approved 2023-09-29: TECHNEGAS KIT (NDA022335 ORIG1) |
| 2023-09-29 | FDA approval | approved | BAXTER HLTHCARE CORP BAX | MICAFUNGIN IN SODIUM CHLORIDE 0.9% | Approved 2023-09-29: MICAFUNGIN IN SODIUM CHLORIDE 0.9% (NDA216142 ORIG1) |
Trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2023-09 | P1/P2 | Philogen S.p.A. | NCT02957019 A Phase I/II Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Rituximab in Relapsed or Refractory Diff | Diffuse Large B-cell Lymphoma (DLBCL) | terminated | 6 |
| 2023-09 est. | P1/P2 | RHEACELL GmbH & Co. KG | NCT03549299 Allogeneic ABCB5-positive Limbal Stem Cells for Treatment of LSCD | Limbal Stem Cell Deficiency | unknown | 16 |
| 2023-09 est. | P1/P2 | Shanghai JMT-Bio Inc. | NCT04255576 Efficacy and Safety of JMT103 in Patients With Giant Cell Tumor of Bone | Giant Cell Tumor of Bone | unknown | 139 |
| 2023-09 est. | P3 | UCB Biopharma SRL | NCT04643483 A Study to Test Efficacy, Safety, and Pharmacokinetics of Certolizumab Pegol in Children and Adolescents With Moderately to Severely Active Crohn's Disease | Crohn's Disease | withdrawn | |
| 2023-09 est. | P2 | Axcella Health, Inc | NCT04880187 Safety, Tolerability, and Efficacy of AXA1125 in NASH With Fibrosis | Non Alcoholic Steatohepatitis (NASH) | unknown | 273 |
| 2023-09 est. | P2 | Sorrento Therapeutics, Inc. | NCT04885972 Study to Evaluate Intra-articular Resiniferatoxin to Treat Moderate to Severe Pain From Knee Osteoarthritis | Osteoarthritis, Knee; Knee Osteoarthritis; Knee Pain Chronic | unknown | 124 |
| 2023-09 est. | P2/P3 | Shanghai Miracogen Inc. | NCT04924699 A Study of MRG002 in the Treatment of Patients With HER2-positive Unresectable Locally Advanced or Metastatic Breast Cancer | Advanced Breast Cancer; Metastatic Breast Cancer | unknown | 350 |
| 2023-09 est. | P2 | NanoMab Technology (UK) Limited | NCT04992715 PD-L1 Expression in Lung Cancer | Non-Small Cell Lung Cancer | unknown | 15 |
| 2023-09 est. | P1/P2 | Shanghai Runshi Pharmaceutical Technology Co., Ltd | NCT05105464 A Study to Investigate the Safety of SYHA1815 in Subjects With Unresectable Locally Advanced or Metastatic Solid Tumors | Locally Advanced Unresectable Carcinoma | unknown | 97 |
| 2023-09 est. | P2 | Lallemand Health Solutions | NCT05198700 The Effect of Probiotics on Symptoms of Infantile Colic | Colic | withdrawn | |
| 2023-09 est. | P3 | Xiamen LP Pharmaceutical Co., Ltd | NCT05199818 Buccal Film vs IV Palonosetron for Prevention of CINV in Cancer Patients Receiving MEC | Chemotherapy-induced Nausea and Vomiting | unknown | 328 |
| 2023-09 est. | P2 | Saol Therapeutics Inc | NCT05311215 Phase II Study to Assess Safety, Pharmacokinetics and Efficacy of SL-1002 for Limb Spasticity | Spasticity | unknown | 32 |
| 2023-09 est. | P2 | Cardurion Pharmaceuticals, Inc. | NCT05312021 Selective PDE9 Inhibition With IMR-687 in Adults With Heart Failure With Preserved Ejection Fraction | Heart Failure With Preserved Ejection Fraction | withdrawn | |
| 2023-09 est. | P2 | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. SBFM | NCT05528679 A Phase II Study of 610 in Participants With Severe Eosinophilic Asthma | Asthma | unknown | 120 |
| 2023-09 est. | P3 | EyePoint Pharmaceuticals, Inc. EYPT | NCT05550350 A Study to Evaluate the Efficacy and Safety of DEXYCU® for the Treatment of Ocular Pain Associated With Cataract Surgery | Cataract | withdrawn | |
| 2023-09 est. | P3 | EyePoint Pharmaceuticals, Inc. EYPT | NCT05550363 A Study to Evaluate the Efficacy and Safety of DEXYCU® for the Treatment of Ocular Pain Associated With Cataract Surgery (2) | Cataract | withdrawn | |
| 2023-09 est. | P1/P2 | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. SBFM | NCT05588908 A Phase Ib/II Study of Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection in Chinese Participants With Acute Gout | Acute Gout | unknown | 120 |
| 2023-09 est. | P2 | Aceragen | NCT05641298 Study to Determine the Efficacy&Safety of ARV-1801(ACG-701) for the Treatment of Cystic Fibrosis Pulmonary Exacerbations | Cystic Fibrosis; Cystic Fibrosis Pulmonary Exacerbation | withdrawn | |
| 2023-09 est. | P2 | Tosk, Inc. | NCT05658016 Phase 2a Study to Evaluate Suppression of Radiotherapy-induced Mucositis by TK112690 | Mucositis | unknown | 24 |
| 2023-09 est. | P2 | Tosk, Inc. | NCT05669521 Phase 2a Study to Evaluate Suppression of 5-Fluorouracil -Induced Mucositis by TK112690 | Mucositis | unknown | 24 |
| 2023-09 est. | P2/P3 | Frontier Biotechnologies Inc. ULCC | NCT05675072 Evaluate the Efficacy and Safety of FB2001 for Inhalation in Patients With Mild to Moderate COVID-19 | Mild to Moderate COVID-19 | unknown | 1336 |
| 2023-09-01 est. | P1/P2 | Takeda TAK | NCT04260009 Pharmacokinetics, Safety, and Efficacy of Brigatinib Monotherapy in Pediatric and Young Adult Participants With ALK+ Anaplastic Large Cell Lymphoma, Inflammator | Anaplastic Lymphoma Kinase Positive (ALK +) Anaplastic Large Cell Lymphoma; Inflammatory Myofibrobla | withdrawn | |
| 2023-09-01 est. | P1/P2 | EMD Serono Research & Development Institute, Inc. | NCT04655183 Study of M4344 in Combination With Niraparib | Advanced Solid Tumor; Breast Cancer | withdrawn | |
| 2023-09-01 | P2 | Stayble Therapeutics | NCT04673461 Study Investigating STA363 Compared to Placebo in Patients With Chronic Discogenic Low Back Pain | Discogenic Pain | completed | 110 |
| 2023-09-01 | P3 | Palatin Technologies, Inc PTN | NCT05201170 A Phase 3, Multi-Center Study Evaluating PL9643 in Patients with Dry Eye | Dry Eye; Dry Eye Syndromes | completed | 575 |
| 2023-09-01 est. | P2/P3 | Ocugen OCGN | NCT05258669 Immuno-bridging and Broadening Study of a Whole, Inactivated COVID-19 Vaccine BBV152 in Healthy Adults | COVID-19 | unknown | 400 |
| 2023-09-01 | P1/P2 | Santiste Medical Inc. | NCT05348343 Activated PRP for Treatment of Androgenetic Alopecia | Androgenetic Alopecia | completed | 17 |
| 2023-09-01 est. | P1/P2 | Shanghai Henlius Biotech | NCT05390528 A Study Evaluating the Safety, Tolerability, Pharmacokinetic and Efficacy of HLX301(TIGIT×PDL1 Bispecific) in Locally Advanced/Metastatic Solid Tumors or Lympho | Advanced Tumors; Lymphoma; Metastatic Tumors | unknown | 30 |
| 2023-09-01 | P2 | Incyte Corporation INCY | NCT05593445 A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Lichen Sclerosus | Lichen Sclerosus | completed | 61 |
| 2023-09-01 est. | P3 | Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd | NCT05679492 Study on the Safety and Efficacy of Meplazumab for Injection Patients COVID-19 | COVID-19 | withdrawn | |
| 2023-09-01 | P2 | Guangdong Longchuangji Pharmaceutical Co., Ltd. | NCT07418918 Live Double Combined Lactobacillus Capsule for Vaginal Use(IIb) | Bacterial Vaginosis | completed | 66 |
| 2023-09-04 | P3 | Kyntra Bio KYNB | NCT04419558 Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF) | Idiopathic Pulmonary Fibrosis | terminated | 372 |
| 2023-09-04 | P2 | Bausch Health Americas, Inc. | NCT05098028 Pharmacokinetics and Pharmacodynamics of Rifaximin Novel Formulations in Patients With Sickle Cell Disease | Sickle Cell Disease | completed | 44 |
| 2023-09-04 | P1/P2 | Eisai Co., Ltd. | NCT05278663 A Study to Assess the Safety, Tolerability, and Pharmacokinetics of E6742 in Systemic Lupus Erythematosus Participants | Lupus Erythematosus, Systemic | completed | 26 |
| 2023-09-04 | P3 | Jiangsu Rec-Biotechnology Co., Ltd. | NCT05398848 Efficacy, Safety and Immunogenicity Study of the Recombinant Two-component COVID-19 Vaccine (CHO Cell)(Recov) | COVID-19 | completed | 7623 |
| 2023-09-04 | P3 | ModernaTX, Inc. | NCT05415462 A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults | Seasonal Influenza | completed | 6102 |
| 2023-09-04 | P3 | Takeda TAK | NCT05543187 A Study of TAK-625 for the Treatment of Progressive Familial Intrahepatic Cholestasis (PFIC) | Progressive Familial Intrahepatic Cholestasis (PFIC) | completed | 5 |
| 2023-09-05 | P1/P2 | AC Immune SA ACIU | NCT04445831 A Study to Evaluate the Safety, Tolerability and Immunogenicity of Tau Targeted Vaccines in Participants With Early Alzheimer's Disease | Alzheimer's Disease; Cognitive Impairment; Tauopathies; Mild Cognitive Impairment; Dementia; Brain D | completed | 57 |
| 2023-09-05 | P2 | Aclaris Therapeutics, Inc. ACRS | NCT05279417 ATI-450 Plus Methotrexate (MTX) Versus Placebo Plus MTX in Participants With Moderate to Severe Active Rheumatoid Arthritis (RA) | Rheumatoid Arthritis | completed | 251 |
| 2023-09-05 | P2 | Sunshine Lake Pharma Co., Ltd. SBFM | NCT05397379 A Safety, Tolerability, Efficacy, and Pharmacokinetics Study of HEC96719 in Subjects With Non-Cirrhotic Non-Alcoholic Steatohepatitis | Non-Alcoholic Steatohepatitis | completed | 68 |
| 2023-09-05 | P2 | MoonLake Immunotherapeutics AG MLTX | NCT05640245 Evaluation of Sonelokimab for the Treatment of Patients With Active Psoriatic Arthritis | Arthritis, Psoriatic | completed | 207 |
| 2023-09-06 | P2 | Actelion | NCT01093326 Clinical Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Ponesimod in Patients With Relapsing-remitting Multiple Sclerosis | Multiple Sclerosis | completed | 353 |
| 2023-09-06 | P2 | Genzyme, a Sanofi Company | NCT02004704 A Long-Term Study of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency | Sphingomyelin Lipidosis | completed | 25 |
| 2023-09-06 | P2 | Palisade Bio PALI | NCT02836470 A Study to Evaluate LB1148 for Return of Gastrointestinal Function and Adhesions in Subjects Undergoing Bowel Resection | Ileus; Post-Operative Adhesions | completed | 112 |
| 2023-09-06 | P3 | Alkermes, Inc. ALKS | NCT03201757 Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 | Schizophrenia; Schizophreniform Disorder; Bipolar I Disorder | completed | 523 |
| 2023-09-06 | P1/P2 | Faron Pharmaceuticals Ltd | NCT03733990 A Study to Evaluate Safety, Tolerability and Preliminary Efficacy of FP-1305 in Cancer Patients (MATINS) | Cancer | completed | 216 |
| 2023-09-06 | P2 | Durect | NCT04563026 A Phase 2b Study in Subjects With Alcoholic Hepatitis to Evaluate Safety and Efficacy of DUR-928 Treatment | Alcoholic Hepatitis | completed | 307 |
| 2023-09-06 | P3 | Zydus Lifesciences Limited | NCT05283837 A Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Immunogenicity of Test Pertuzumab (ZRC-3277, Cadila Healthcare Ltd.,) | Metastatic Breast Cancer | completed | 268 |
| 2023-09-06 | P3 | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | NCT05846568 Study to Evaluate GR1801's Efficacy and Safety | Rabies Post-exposure Prophylaxis | completed | 1200 |
| 2023-09-07 | P3 | AstraZeneca AZN | NCT03519971 Study of Durvalumab Given With Chemoradiation Therapy in Patients With Unresectable Non-small Cell Lung Cancer | Non-Small Cell Lung Cancer | completed | 328 |
| 2023-09-07 | P1/P2 | Shasqi, Inc. | NCT04106492 Phase 1/2a Study of SQ3370 in Patients With Advanced Solid Tumors | Cancer | terminated | 53 |
| 2023-09-07 | P2 | Calcilytix Therapeutics, Inc., a BridgeBio company | NCT04581629 Safety, Tolerability, and Efficacy of Encaleret in Participants With Autosomal Dominant Hypocalcemia (ADH) Type 1 | Autosomal Dominant Hypocalcemia (ADH); Autosomal Dominant Hypocalcemia Type 1 (ADH1) | completed | 13 |
| 2023-09-07 | P2 | OliPass Corporation | NCT05216341 Study of OLP-1002 Injections for Reducing Moderate to Severe Pain Due to Osteoarthritis in Hip and/or Knee Joint | Osteoarthritis | completed | 134 |
| 2023-09-07 | P1/P2 | Merck Sharp & Dohme LLC MRK | NCT05394350 A Study of MK-1088 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-1088-002) | Advanced Solid Tumors | terminated | 27 |
| 2023-09-07 | P1/P2 | Teon Therapeutics, Inc. | NCT05525455 TT-816 As Monotherapy or in Combination with a PD-1 Inhibitor in Patients with Advanced Cancers (SEABEAM) (MK3475-E88) | Advanced Cancer; Advanced Solid Tumor; Cancer; Oncology | terminated | 9 |
| 2023-09-07 | P2 | Pharmasoft | NCT06903156 Efficacy and Safety of Different Dosages of Mexidol® in Patients With Primary Open-angle Glaucoma (POAG) | Primary Open-Angle Glaucoma (POAG) | completed | 102 |
| 2023-09-08 | P1/P2 | AstraZeneca AZN | NCT04630756 AZD4573 in Novel Combinations With Anti-cancer Agents in Patients With Advanced Blood Cancer | Advanced Haematological Malignancies | completed | 40 |
| 2023-09-08 | P2 | Merck Sharp & Dohme LLC MRK | NCT04663321 Efficacy and Safety of MK-1942 When Added to Stable Antidepressant Therapy in Participants With Treatment-Resistant Depression (TRD) (MK-1942-006) | Treatment Resistant Depression | terminated | 99 |
| 2023-09-08 est. | P2/P3 | Reistone Biopharma Company Limited | NCT04717310 Evaluate the Efficacy and Safety of Topical SHR0302 Ointment in Patients With Mild-to-Moderate Atopic Dermatitis | Atopic Dermatitis | unknown | 645 |
| 2023-09-08 | P3 | Harmony Biosciences Management, Inc. HRMY | NCT05156047 A Phase 3 Study to Assess the Safety and Efficacy of Pitolisant in Adult Patients With Idiopathic Hypersomnia | Idiopathic Hypersomnia | completed | 214 |
| 2023-09-08 | P1/P2 | Fusion Pharmaceuticals Inc. HTOO | NCT05363605 A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours | Advanced Solid Tumor; Head and Neck Squamous Cell Carcinoma; Bladder Carcinoma; Susceptible FGFR3 Ge | terminated | 6 |
| 2023-09-10 est. | P3 | Sinovac Biotech (Colombia) S.A.S. SVA | NCT05433272 Immunogenicity and Safety Study of One Booster Dose of Trivalent COVID-19 Vaccine (Vero Cell), Inactivated | COVID-19 | unknown | 1400 |
| 2023-09-11 | P3 | AstraZeneca AZN | NCT03778957 A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocel | Hepatocellular Carcinoma | active not recruiting | 724 |
| 2023-09-11 | P3 | CSL Behring | NCT04167514 Treatment of GVHD in Hematopoietic Stem Cell Transplant (HSCT) Recipients Using AAT Plus Corticosteroids (CS) Compared With Corticosteroids Alone | Graft Versus Host Disease (GVHD) | completed | 136 |
| 2023-09-11 | P3 | AbbVie ABBV | NCT04195698 Open-Label Extension Study of Upadacitinib in Adult Participants With Moderate to Severe Atopic Dermatitis | Atopic Dermatitis | completed | 475 |
| 2023-09-11 | P2 | InterveXion Therapeutics, LLC | NCT05034874 Multiple-Dose Study to Evaluate the Safety and Efficacy of IXT-m200 | Methamphetamine-dependence; Methamphetamine Abuse | terminated | 61 |
| 2023-09-11 | P3 | Galderma R&D | NCT05052983 A Study to Evaluate the Durability of Response and Safety of Nemolizumab for 24 Weeks in Participants With Prurigo Nodularis | Prurigo Nodularis | completed | 34 |
| 2023-09-11 | P2 | Eloxx Pharmaceuticals, Inc. ELOX | NCT05448755 A Study of ELX-02 in Patients With Alport Syndrome | Alport Syndrome | completed | 3 |
| 2023-09-11 | P3 | BioXcel Therapeutics Inc BTAIQ | NCT05665088 Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY III) | Agitation; Dementia | terminated | 13 |
| 2023-09-11 | P2 | Bial - Portela C S.A. | NCT06597084 Anti-epileptogenic Effects of Eslicarbazepine Acetate | Post Stroke Epilepsy | completed | 129 |
| 2023-09-12 | P1/P2 | Rocket Pharmaceuticals Inc. RCKT | NCT03812263 A Clinical Trial to Evaluate the Safety and Efficacy of RP-L201 in Subjects With Leukocyte Adhesion Deficiency-I | Leukocyte Adhesion Defect - Type I | completed | 9 |
| 2023-09-12 | P2 | Reneo Pharma Ltd | NCT04535609 An Efficacy and Safety Study of 24 Week Treatment With Mavodelpar (REN001) in Primary Mitochondrial Myopathy Patients | Primary Mitochondrial Myopathy | completed | 213 |
| 2023-09-12 | P2 | Ocelot Bio, Inc | NCT05309200 A Study of OCE-205 in Participants With Cirrhosis With Ascites Who Developed Hepatorenal Syndrome-Acute Kidney Injury | Cirrhosis; Ascites; Hepatorenal Syndrome; Acute Kidney Injury | completed | 47 |
| 2023-09-13 | P3 | Novartis Pharmaceuticals NVS | NCT04181762 Study of Safety, Efficacy and Tolerability of Secukinumab Versus Placebo, in Combination With SoC Therapy, in Patients With Active Lupus Nephritis | Lupus Nephritis | terminated | 275 |
| 2023-09-13 | P3 | Gilead Sciences GILD | NCT04313881 Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS) | Myelodysplastic Syndromes | terminated | 539 |
| 2023-09-13 | P2 | Pfizer PFE | NCT04707313 A Study to Evaluate the Efficacy and Safety of PF-06882961 in Adults With Obesity | Obesity | completed | 628 |
| 2023-09-13 | P2 | Keymed Biosciences Co.Ltd | NCT05186909 A Study of CM310 in Subjects With Moderate to Severe Asthma | Asthma | completed | 52 |
| 2023-09-13 | P2 | Pfizer PFE | NCT05799495 A Study to Understand the Effect and Safety of the Study Medicine PF-07817883 in Adults Who Have Symptoms of COVID-19 But Are Not Hospitalized | SARS-CoV-2 Infection | completed | 240 |
| 2023-09-14 | P2 | Celgene | NCT03257631 A Study of Pomalidomide Monotherapy for Children and Young Adults With Recurrent or Progressive Primary Brain Tumors | Central Nervous System Neoplasms; Medulloblastoma | completed | 53 |
| 2023-09-14 | P3 | Jiangsu HengRui Medicine Co., Ltd. | NCT04613674 A Study of Camrelizumab Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) | Triple Negative Breast Cancer | completed | 441 |
| 2023-09-14 | P3 | Helixmith Co., Ltd. | NCT04873232 A 6-Month Extension Study of VMDN-003-2 to Assess Engensis in Participants With Painful Diabetic Peripheral Neuropathy | Diabetic Peripheral Neuropathy | completed | 106 |
| 2023-09-14 | P2 | Vaxcell Bio, Co., Ltd. | NCT05040438 Natural Killer (NK) Cell Therapy in Locally Advanced HCC | Locally Advanced Hepatocellular Carcinoma | completed | 17 |
| 2023-09-14 | P2 | BioCryst Pharmaceuticals BCRX | NCT05116774 BCX9930 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in Participants With Inadequate Response to C5 Inhibitor Therapy | Paroxysmal Nocturnal Hemoglobinuria (PNH) | terminated | 12 |
| 2023-09-14 | P2 | Sanofi SNY | NCT05179603 A Study of SAR444245 With or Without Other Anticancer Therapies for the Treatment of Adults and Adolescents With Relapsed or Refractory B Cell Lymphoma (Master | Classic Hodgkin Lymphoma; Diffuse Large B-cell Lymphoma | terminated | 14 |
| 2023-09-14 | P3 | Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd | NCT05813587 To Evaluate the Safety and Efficacy of Meplazumab in Treatment of Post-COVID-19 | Post-COVID-19 | completed | 121 |
| 2023-09-14 | P3 | ViiV Healthcare | NCT05896748 Study to Assess the Effects of Cabotegravir (CAB) and Rilpivirine (RPV) Long-Acting (LA) Injections Following Sub-cutaneous (SC) Administration Compared With In | Human Immunodeficiency Virus Type 1 (HIV-1) | completed | 94 |
| 2023-09-15 | P3 | Intercept Pharmaceuticals | NCT02548351 Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment | Non Alcoholic Steatohepatitis (NASH) | terminated | 2477 |
| 2023-09-15 | P3 | Bayer | NCT02626455 Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL) | Lymphoma, Non-Hodgkin | terminated | 551 |
| 2023-09-15 | P1/P2 | ImmuneSensor Therapeutics Inc. | NCT04020185 Safety and Efficacy Study of IMSA101 in Refractory Malignancies | Solid Tumor, Adult | completed | 40 |
| 2023-09-15 | P3 | Novartis Pharmaceuticals NVS | NCT04929249 A Randomized Study to Evaluate the Effect of an "Inclisiran First" Implementation Strategy Compared to Usual Care in Patients With Atherosclerotic Cardiovascula | Atherosclerotic Cardiovascular Disease | completed | 450 |
| 2023-09-15 est. | P1/P2 | Shanghai Henlius Biotech | NCT05102214 HLX301 (TIGIT×PDL1 Bispecific) in Patients With Locally Advanced or Metastatic Solid Tumors | Locally Advanced or Metastatic Solid Tumors; Non-small Cell Lung Cancer | unknown | 150 |
| 2023-09-15 | P2 | Shanghai Hengrui Pharmaceutical Co., Ltd. | NCT05549947 Efficacy and Safety Study of SHR-1819 Injection in Adult Patients With Severe Atopic Dermatitis | Moderate to Severe Atopic Dermatitis | completed | 158 |
| 2023-09-15 | P3 | LianBio LLC | NCT05629390 Trial to Evaluate the Efficacy and Safety of TP-03, LIBRA Study | Blepharitis | completed | 163 |
| 2023-09-15 | P2/P3 | Beijing Protgen Biotechnology Development Co., Ltd. | NCT05858853 Phase II/III of Recombinant Human Serum Albumin | Cirrhotic Ascites | completed | 92 |
| 2023-09-15 | P2 | NFL Biosciences SAS | NCT06091826 Study Assessing Efficacy and Safety of NFL-101 on Reduction of Reinforcing Properties of Cigarettes (PRECESTO) | Smoking Cessation; Nicotine Dependence | completed | 34 |
| 2023-09-15 | P3 | Catalysis SL | NCT06361992 Efficacy and Safety of Blue Cap for the Treatment of Atopic Dermatitis in Children | Atopic Dermatitis; Atopic Dermatitis and Related Conditions; Atopic Dermatitis Eczema; Atopic Dermat | completed | 58 |
| 2023-09-18 | P2 | Merck Sharp & Dohme LLC MRK | NCT02453594 Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-087/KEYNOTE-087) | Hodgkin Lymphoma | completed | 211 |
| 2023-09-18 | P2/P3 | Sun Pharmaceutical Industries Limited | NCT03552276 Long-Term Extension Trial of Tildrakizumab to Prove Its Safety in Subjects With Psoriatic Arthritis Who Have Previously Completed Study With Tildrakizumab. | Psoriatic Arthritis | completed | 281 |
| 2023-09-18 | P2 | Imbria Pharmaceuticals, Inc. | NCT04826185 A Study to Evaluate the Safety, Tolerability, and Efficacy of IMB-1018972 in Patients With Non-obstructive Hypertrophic Cardiomyopathy Trial | Non-obstructive Hypertrophic Cardiomyopathy | completed | 67 |
| 2023-09-18 | P3 | LEO Pharma | NCT04949841 Open-label Multi-site Extension Trial in Subjects Who Completed the DELTA 1 or DELTA 2 Trials | Chronic Hand Eczema | completed | 801 |
| 2023-09-18 | P3 | Rhythm Pharmaceuticals, Inc. RYTM | NCT04966741 Setmelanotide in Pediatric Participants With Rare Genetic Diseases of Obesity | Bardet-Biedl Syndrome; POMC Deficiency Obesity; PCSK1 Deficiency Obesity; LEPR Deficiency Obesity | completed | 12 |
| 2023-09-18 | P2 | BioCryst Pharmaceuticals BCRX | NCT05116787 BCX9930 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in Participants Not Receiving Other Complement Inhibitor Therapy | Paroxysmal Nocturnal Hemoglobinuria (PNH) | terminated | 12 |
| 2023-09-18 | P3 | Invex Therapeutics Ltd. | NCT05347147 A Trial to Determine the Efficacy and Safety of Presendin in IIH | Idiopathic Intracranial Hypertension | terminated | 14 |
| 2023-09-18 | P2 | Dompé Farmaceutici S.p.A | NCT05368402 Clinical Trial on Ladarixin Adjunctive Therapy to Improve Glycemic Control in Type 1 Diabetes. | Type 1 Diabetes | terminated | 3 |
| 2023-09-18 | P2 | Xenon Pharmaceuticals Inc. XENE | NCT05376150 A Study to Evaluate the Safety, Tolerability and Efficacy of XEN1101 in Major Depressive Disorder | Major Depressive Disorder | completed | 168 |
| 2023-09-18 | P3 | Bausch & Lomb Incorporated BLCO | NCT05815758 Evaluation of the Safety and Pharmacokinetics of Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Combination Ophthalmic Solution | Allergic Conjunctivitis | completed | 512 |
| 2023-09-19 | P2/P3 | Humacyte, Inc. HUMA | NCT03005418 Humacyte Acellular Tissue Engineered Vessel (ATEV) in Patients With Vascular Trauma | Trauma; Vascular System Injury | completed | 72 |
| 2023-09-19 | P2 | AstraZeneca AZN | NCT03239340 A Molecular Profiling Study of Patients With EGFR Mutation-positive Locally Advanced or Metastatic NSCLC Treated With Osimertinib | EGFR Mutation Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer | completed | 154 |
| 2023-09-19 | P3 | AstraZeneca AZN | NCT03961815 Open-label Extension Study of Brazikumab in Crohn's Disease | Crohn's Disease; IBD | terminated | 18 |
| 2023-09-19 | P2/P3 | Janssen Research & Development, LLC | NCT04033445 A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis | Ulcerative Colitis | active not recruiting | 1064 |
| 2023-09-19 | P2 | Novartis Pharmaceuticals NVS | NCT04064242 Study of Efficacy, Safety and Tolerability of CMK389 in Patients With Chronic Pulmonary Sarcoidosis | Pulmonary Sarcoidosis | completed | 62 |
| 2023-09-19 | P3 | George Medicines PTY Limited | NCT04518306 Efficacy and Safety of GMRx2 Compared to Placebo for the Treatment of Hypertension | Hypertension | completed | 755 |
| 2023-09-19 | P3 | Sound Pharmaceuticals, Incorporated SOGP | NCT04677972 SPI-1005 for the Treatment of Meniere's Disease | Meniere Disease; Ménière | completed | 220 |
| 2023-09-19 | P1/P2 | Shanghai Antengene Corporation Limited | NCT04691141 A Study to Evaluating the Pharmacokinetics, Safety, and Efficacy of ATG 016 Monotherapy in IPSS-R Intermediate Risk and Above Myelodysplastic Syndrome (MDS) | Myelodysplastic Syndrome | terminated | 15 |
| 2023-09-19 | P3 | Biocon Biologics Inc. | NCT05637515 Hulio Interchangeability to Humira®, Comparing Pharmacokinetics, Efficacy, Safety and Immunogenicity | Moderate Chronic Plaque Psoriasis; Severe Chronic Plaque Psoriasis | completed | 374 |
| 2023-09-20 | P3 | Janssen Research & Development, LLC | NCT03170518 A Study to Investigate the Efficacy and Safety of Canagliflozin in Children and Adolescents (>=10 to <18 Years) With Type 2 Diabetes Mellitus | Diabetes Mellitus, Type 2 | completed | 171 |
| 2023-09-20 | P2 | SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany | NCT03962543 MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas | Plexiform Neurofibroma; Neurofibromatosis Type 1 (NF1) | active not recruiting | 114 |
| 2023-09-20 | P2 | Hoffmann-La Roche | NCT04665843 A Study of Atezolizumab Plus Tiragolumab and Atezolizumab Plus Placebo as First-Line Treatment in Participants With Recurrent/Metastatic PD-L1 Positive Squamous | Squamous Cell Carcinoma of Head and Neck | completed | 123 |
| 2023-09-20 est. | P3 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | NCT04956328 Study of Obeticholic Acid(OCA) Combination With Ursodeoxycholic Acid (UDCA) in Patients With Primay Biliary Cirrhosis (PBC) | Primary Biliary Cirrhosis | unknown | 120 |
| 2023-09-20 | P2 | Novartis Pharmaceuticals NVS | NCT05086744 Basket Study to Assess Efficacy, Safety and PK of Iptacopan (LNP023) in Autoimmune Benign Hematological Disorders | Immune Thrombocytopenia (ITP); Cold Agglutinin Disease (CAD) | terminated | 19 |
| 2023-09-20 | P2 | Xalud Therapeutics, Inc. | NCT05196919 Safety and Efficacy of XT-150 for Facet Joint Osteoarthritis Pain | Facet Joint Pain; Back Pain; Inflammation | completed | 75 |
| 2023-09-21 | P2 | Progenics Pharmaceuticals, Inc. | NCT03939689 I-131-1095 Radioligand Plus Enzalutamide vs Enzalutamide for mCRPC That Progressed During Abiraterone (ARROW). | Metastatic Prostate Cancer; Castration-resistant Prostate Cancer; Prostatic Neoplasm; Cancer of the | completed | 120 |
| 2023-09-21 | P3 | Merck Sharp & Dohme LLC MRK | NCT03976362 A Study of Pembrolizumab (MK-3475) With or Without Maintenance Olaparib in First-line Metastatic Squamous Non-small Cell Lung Cancer (NSCLC, MK-7339-008/KEYLYNK | Carcinoma, Squamous Cell, Non-small-cell Lung | completed | 851 |
| 2023-09-21 | P1/P2 | NGM Biopharmaceuticals, Inc | NCT04068896 Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy | Pancreatic Cancer; Metastatic Castration-resistant Prostate Cancer; Bladder Cancer; Melanoma; Non-sm | completed | 89 |
| 2023-09-21 | P2 | Imbria Pharmaceuticals, Inc. | NCT04826172 Exploratory Study on the Safety, Tolerability, and Pharmacodynamics of IMB-1018972 in Subjects With Angina Due to Obstructive Coronary Artery Disease (IMPROVE-I | Ischemia; Coronary Artery Disease | completed | 58 |
| 2023-09-21 | P2 | Emerald Clinical Inc. | NCT04974008 Osteosarcoma Maintenance Therapy With OST31-164 | Bone Cancer | active not recruiting | 39 |
| 2023-09-21 | P1/P2 | NKGen Biotech, Inc. | NCT05099549 Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing Cancers | Squamous Cell Carcinoma of Head and Neck; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Adva | terminated | 11 |
| 2023-09-21 est. | P2 | Pfizer PFE | NCT05545319 A Study to Learn About the Medicine Called Nirmatrelvir Used in Combination With Ritonavir in People With Weakened Immune Systems or at Increased Risk for Poor | Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2); Coronavirus Disease 2019 (COVID-19); I | withdrawn | |
| 2023-09-22 | P2 | Kite, A Gilead Company | NCT02601313 Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 1 and Cohort 2) | Relapsed/Refractory Mantle Cell Lymphoma | completed | 105 |
| 2023-09-22 | P3 | Sanofi Pasteur, a Sanofi Company SNY | NCT03537508 Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants a | Healthy Volunteers (Meningococcal Infection) | completed | 2627 |
| 2023-09-22 | P2 | Juno Therapeutics, a Subsidiary of Celgene | NCT03744676 A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OU | Lymphoma, Non-Hodgkin; Lymphoma; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Neoplasms; Neopl | completed | 104 |
| 2023-09-22 | P3 | Sanofi SNY | NCT04154956 SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small | Non-small Cell Lung Cancer Metastatic | terminated | 389 |
| 2023-09-22 | P2 | Novartis Pharmaceuticals NVS | NCT04346654 A Study to Assess Efficacy and Safety of Eltrombopag in Combination With a Short Course of Dexamethasone in Patients With Newly Diagnosed ITP | Immune Thrombocytopenia (ITP) | completed | 26 |
| 2023-09-22 | P2 | AstraZeneca AZN | NCT04595370 Efficacy, Safety and Tolerability of AZD9977 and Dapagliflozin in Participants With Heart Failure and Chronic Kidney Disease | Heart Failure; Chronic Kidney Disease | completed | 153 |
| 2023-09-22 | P2 | Karyopharm Therapeutics Inc KPTIQ | NCT04768881 Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced Melanoma | Locally Advanced Unresectable or Metastatic Melanoma | terminated | 15 |
| 2023-09-22 | P1/P2 | Hoffmann-La Roche | NCT05116202 A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morpheus-Melanoma) | Melanoma | completed | 110 |
| 2023-09-22 | P2 | Shanghai Mabgeek Biotech.Co.Ltd | NCT05466877 A Study of MG-K10 in Subjects With Atopic Dermatitis | Atopic Dermatitis | unknown | 163 |
| 2023-09-25 | P3 | Biotest | NCT03444324 Adjusted Fibrinogen Replacement Strategy | Bleeding Disorder; Hypofibrinogenemia; Acquired | completed | 222 |
| 2023-09-25 est. | P1/P2 | Immunocore Ltd IMCR | NCT03973333 Safety and Efficacy of IMC-C103C as Monotherapy and in Combination With Atezolizumab | Select Advanced Solid Tumors | withdrawn | |
| 2023-09-25 | P2 | Ventyx Biosciences, Inc | NCT05655299 VTX958 Versus Placebo for the Treatment of Moderate to Severe Psoriasis | Psoriasis | terminated | 222 |
| 2023-09-26 | P2 | NanOlogy, LLC (doing business as Intryx Therapeutics, LLC) | NCT04314895 Trial of NanoPac Intratumoral Injection in Lung Cancer | Lung Cancer, Nonsmall Cell; Lung Cancer; Lung Cancer, Small Cell; Neoplasm of Lung | completed | 18 |
| 2023-09-26 | P2 | Novartis Pharmaceuticals NVS | NCT04722666 Study of Efficacy and Safety of MIJ821 in Addition to Comprehensive Standard of Care on the Rapid Reduction of Symptoms of Major Depressive Disorder in Subjects | Major Depressive Disorder With Suicidal Ideation With Intent | terminated | 199 |
| 2023-09-26 | P3 | ALK-Abelló A/S | NCT04881461 A Study in Adults With Grass Pollen-induced Rhinoconjunctivitis | Allergy | completed | 445 |
| 2023-09-26 | P2 | BeiGene | NCT05116085 Efficacy and Safety of Tislelizumab (BGB-A317) as Neo-Adjuvant Treatment in Participants With Colorectal Cancer | Colorectal Cancer | completed | 33 |
| 2023-09-27 | P3 | Hoffmann-La Roche | NCT03452137 A Study of Atezolizumab (Anti-PD-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carci | Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN) | terminated | 406 |
| 2023-09-27 | P1/P2 | Kartos Therapeutics, Inc. | NCT04113616 An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or | Relapsed or Refractory Acute Myeloid Leukemia (AML); Acute Myeloid Leukemia (AML), Secondary to Myel | terminated | 70 |
| 2023-09-27 | P3 | Takeda TAK | NCT05027308 A Study of Teduglutide in Japanese Children With Short Bowel Syndrome Aged 4 Months or Older | Short Bowel Syndrome | completed | 3 |
| 2023-09-27 | P2 | Pfizer PFE | NCT05567952 A Study to Learn About a Repeat 5-Day Treatment With the Study Medicines (Called Nirmatrelvir/Ritonavir) in People 12 Years Old or Older With Return of COVID-19 | COVID-19 | completed | 436 |
| 2023-09-27 | P2 | Merck Sharp & Dohme LLC MRK | NCT05602727 Efficacy and Safety of MK-1942 as an Adjunct Therapy in Participants With Mild to Moderate Alzheimer's Disease Dementia (MK-1942-008) | Alzheimer's Disease | terminated | 99 |
| 2023-09-27 | P1/P2 | Exscientia AI Limited | NCT05920408 Study to Assess EXS21546 in Combination in Patients With Advanced Solid Tumours | Advanced Solid Tumours | terminated | 6 |
| 2023-09-27 | P3 | AryoGen Pharmed Co. | NCT06137092 rFVIII-Fc (Produced by AryoGen Pharmed Co.) Pharmacokinetic Study | Severe Hemophilia A | completed | 50 |
| 2023-09-28 | P3 | Bristol-Myers Squibb BMY | NCT03138512 A Study Comparing Nivolumab, Nivolumab in Combination With Ipilimumab and Placebo in Participants With Localized Kidney Cancer Who Underwent Surgery to Remove P | Carcinoma, Renal Cell | completed | 1641 |
| 2023-09-28 | P2 | CoImmune | NCT04203901 Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma | Advanced Renal Cell Carcinoma | terminated | 16 |
| 2023-09-28 | P1/P2 | Spur Therapeutics | NCT04455230 A Long Term Follow-Up Study of Fabry Disease Subjects Treated With FLT190 | Fabry Disease; Lysosomal Storage Diseases | terminated | 3 |
| 2023-09-28 | P2 | Oxurion | NCT04527107 A Study to Evaluate THR-149 Treatment for Diabetic Macular Oedema | Diabetes Mellitus; Diabetic Retinopathy; Diabetic Macular Edema | completed | 135 |
| 2023-09-28 | P3 | Jazz Pharmaceuticals JAZZ | NCT05288283 Efficacy and Safety of GWP42003-P Oral Solution in Children With Epilepsy With Myoclonic-atonic Seizures | Seizures Associated With EMAS | terminated | 3 |
| 2023-09-28 | P2 | Altimmune, Inc. ALT | NCT05295875 Efficacy and Safety of ALT-801 in the Treatment of Obesity | Obesity/Overweight | completed | 391 |
| 2023-09-28 | P2 | Allgenesis Biotherapeutics Inc. | NCT05301751 A Single Ascending Dose Cohort Study of AG-73305 in DME Patients | Diabetic Macular Edema | completed | 25 |
| 2023-09-28 | P2 | Celldex Therapeutics CLDX | NCT05368285 A Phase 2 Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria | Chronic Spontaneous Urticaria | completed | 208 |
| 2023-09-28 | P1/P2 | Shanghai Jun Pai Ying Shi Therapeutics Co., Ltd. | NCT05824455 A Clinical Study of IMP4297 Capsule (JS109) Combined With Irinotecan in the Treatment of Advanced Malignant Solid Tumors | Advanced Solid Tumors | terminated | 4 |
| 2023-09-28 | P1/P2 | Gan and Lee Pharmaceuticals, USA | NCT06256523 A Study of GZR18 Injection in Chinese Adult Patients With Type 2 Diabetes Mellitus (T2DM) | Type 2 Diabetes | completed | 72 |
| 2023-09-28 | P2 | Beijing Greatway Pharmaceutical Technology Co.,Ltd. | NCT06796868 A Study to Evaluate Efficacy and Safety of GW117 Tablets in Major Depressive Disorder | Major Depressive Disorder (MDD) | completed | 280 |
| 2023-09-29 | P2/P3 | Hoffmann-La Roche | NCT04191499 A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Participants With PIK3CA-Mutant, | Breast Cancer | active not recruiting | 325 |
| 2023-09-29 | P2 | Celgene | NCT04477850 A Study to Evaluate the Efficacy, Drug Levels and Safety of Luspatercept (ACE-536) for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk | Myelodysplastic Syndromes | completed | 30 |
| 2023-09-29 | P3 | Shionogi | NCT04569084 Efficacy and Safety Study of Oral Edaravone Administered in Subjects With ALS | ALS | terminated | 384 |
| 2023-09-29 | P3 | Shionogi | NCT05151471 Efficacy and Safety Extension Study of Oral Edaravone Administered in Subjects With ALS | ALS | terminated | 202 |
| 2023-09-29 | P2 | Longeveron Inc. LGVN | NCT05233774 Lomecel-B Effects on Alzheimer's Disease | Mild Alzheimer's Disease | completed | 50 |
| 2023-09-29 | P3 | Otsuka Pharmaceutical Development & Commercialization, Inc. | NCT05257265 A Trial of Centanafadine Efficacy and Safety in Adolescents With Attention- Deficit/Hyperactivity Disorder | Attention-Deficit/Hyperactivity Disorder | completed | 459 |
| 2023-09-29 | P3 | Mersana Therapeutics | NCT05329545 Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer (UP-NEXT) | High Grade Serous Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer | terminated | 20 |
| 2023-09-29 | P2 | Janssen Research & Development, LLC | NCT05364554 A Long-term Extension Study of JNJ-77242113 in Participants With Moderate-to-Severe Plaque Psoriasis | Plaque Psoriasis | completed | 227 |
| 2023-09-29 | P2 | Tonix Pharmaceuticals, Inc. TNXP | NCT05686408 Study to Evaluate TNX-601 ER Monotherapy Versus Placebo in Patients With Major Depressive Disorder (MDD) | Depression; Depressive Disorder; Depressive Symptoms; Depressive Disorder, Major; Depressive Episode | completed | 132 |
| 2023-09-29 | P3 | Janssen Research & Development, LLC | NCT05784129 A Study of Guselkumab for the Treatment of Participants With Crohn's Disease After Surgical Resection | Crohn's Disease | terminated | 4 |
| 2023-09-29 | P3 | Newsoara Biopharma Co., Ltd. | NCT07712705 HPP737 in Adult Patients With Moderate-to-severe Plaque Psoriasis. | Psoriasis | completed | 515 |
| 2023-09-30 est. | P2 | Viravaxx AG | NCT03625934 Study to Evaluate Induction of HBV Virus Neutralizing Antibodies Using VVX001 | Hepatitis B | unknown | 84 |
| 2023-09-30 | P3 | BioVie Inc. BIVI | NCT04669028 A Phase 3 Study of NE3107 in Probable Alzheimer's Disease | Alzheimer Disease | completed | 439 |
| 2023-09-30 est. | P1/P2 | RaND Biosciences RAND | NCT04733521 A Phase 1/2 Study of SC-43 in Combination With Cisplatin | Advanced Non-small-cell Lung Cancer; Advanced Biliary Tract Cancer | unknown | 100 |
| 2023-09-30 est. | P3 | Biosolution Co., Ltd. | NCT05051332 Phase 3 Clinical Trial of CartiLife® in Korea | Articular Cartilage Defect; Articular Cartilage Degeneration | unknown | 104 |
| 2023-09-30 est. | P3 | Jiangsu HengRui Medicine Co., Ltd. | NCT05074602 A Study to Evaluate the Efficacy and Safety of SHR8008 vs. Fluconazole in Subjects With Recurrent Vulvovaginal Candidiasis | Recurrent Vulvovaginal Candidiasis | unknown | 196 |
| 2023-09-30 est. | P2 | Shanghai JMT-Bio Inc. | NCT05132777 Efficacy and Safety of JMT101 Combined With Osimertinib in Patients With Non-Small Cell Lung Cancer | Locally Advanced or Metastatic Non-Small Cell Lung Cancer; EGFR Exon20 Insertion Mutations | unknown | 155 |
| 2023-09-30 est. | P2 | PT. Kimia Farma (Persero) Tbk | NCT05172193 Safety & Immunogenicity of Booster SARS-CoV-2 Vaccine (Vero Cell) | COVID-19 | unknown | 600 |
| 2023-09-30 | P1/P2 | Alaunos Therapeutics TCRT | NCT05194735 Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors | Gynecologic Cancer; Colorectal Cancer; Pancreatic Cancer; Non-small Cell Lung Cancer; Cholangiocarci | terminated | 8 |
| 2023-09-30 est. | P2/P3 | Viriom | NCT05204394 Study to Evaluate Efficacy and Safety of Switching to VM-1500A-LAI + 2NRTIs From the 1st Line Standard of Care Therapy | HIV-1-infection | unknown | 438 |
| 2023-09-30 est. | P3 | Mabwell (Shanghai) Bioscience Co., Ltd. | NCT05324774 Efficacy and Safety of 9MW0813 in Subjects With Diabetic Macular Edema | Diabetic Macular Edema | unknown | 346 |
| 2023-09-30 | P3 | Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. | NCT05577468 Efficacy and Safety of Tegoprazan Versus Esomeprazole-containing Bismuth Quadruple Therapy for Eradication of Helicobacter Pylori | Helicobacter Pylori Infection | completed | 561 |
| 2023-09-30 est. | P3 | Synmosa Biopharma Corp. | NCT05895877 Evaluate the Efficacy and Safety of Goofice® (Elobixibat) in Patients With Chronic Constipation | Constipation | unknown | 351 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.